Lipologics manufactures the HNOVA™ platform toward GMP-grade batches — the practical bridge between formulation and clinical or commercial-grade supply.
Formulation, characterisation and manufacturing sit on one site. A formulation developed on the bench is scaled and documented without changing hands.
HNOVA™ manufacturing sits on Hoynoza's KIADB campus in Jigani, Bengaluru — alongside the analytical and quality infrastructure that supports batch release.
Batches are made under quality standards built for global regulatory and commercialisation readiness, not retrofitted onto a bench-scale process.
Plant-derived phosphatidylcholine is hydrated and prepared for vesicle formation.
The active is entrapped within the forming vesicles using the HNOVA™ process.
Vesicles are sized to a uniform distribution and checked against specification.
Material is purified, filled and prepared for the target format.
Stability and release testing complete the batch record before dispatch.
A liposomal formulation moves through lipid hydration, precision nano-encapsulation, particle sizing and fill — with particle size and encapsulation checked at each stage.
This scale range is the practical bridge between preclinical formulation and clinically meaningful supply — large enough for real programme volumes, capital-efficient while demand is proven out.
HNOVA™ manufacturing sits on Hoynoza's KIADB campus in Jigani, Bengaluru — alongside the analytical and quality infrastructure that supports batch release.
Every step under one roof.
Liposomal formulation and stability engineering for new actives.
Particle size, encapsulation efficiency and stability testing.
Taking a bench formulation toward GMP-grade batch scale.
Batch records, Certificates of Analysis and regulatory documentation.
Transfer of process and know-how to partner manufacturing sites.
A plant-based lipid source and clean-label approach throughout.
On Hoynoza's KIADB campus in Jigani, Bengaluru, alongside its analytical and quality infrastructure.
Formulation and pilot development, scaling toward GMP-grade batches. The target GMP batch scale is 100–500 L; scope is confirmed per programme.
Technology transfer is one of the ways partners work with Lipologics. Scope and timelines are agreed per programme.
We do not state a certification on this site unless it has been confirmed in writing for your programme. Ask us for current status and scope.